Performance of 177Lu-DOTATATE-based peptide receptor radionuclide therapy in metastatic gastroenteropancreatic neuroendocrine tumor

Objectives To assess the performance of 177Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) in metastatic gastroenteropancreatic neuroendocrine tumor (GEP-NET) and correlate it with primary tumor site, tumor proliferation index, and dual tracer imaging characteristics. Materials and methods Fifty patients (M : F 33 : 17, age: 26–71 years) with histopathologically confirmed metastatic/inoperable NETs who had undergone at least three...